Finally, ivosidenib gained approval for relapsed/refractory IDH1-mutant MDS based on a phase I study (AG120-C-001) due to the resolution of transfusion dependence in a significant fraction of patients and attainment of CR in 7 of 18 relapsed/refractory MDS patients [94]. This evidence concerns the gene IDH1 and myelodysplastic syndrome.